# Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

> **NCT00511095** · PHASE2 · COMPLETED · sponsor: **Dynavax Technologies Corporation** · enrollment: 207 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** HEPLISAV

## Key facts

- **NCT ID:** NCT00511095
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-10
- **Final completion:** 2008-03
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2019-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00511095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00511095, "Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00511095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*